Table: Taisho Pharmaceutical HD - 9-MTH group results
Jan 30 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Dec 31, 2018 Dec 31, 2017 Mar 31, 2019
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 199.90 215.80 261.50
(-7.4 pct) (-0.3 pct) (-6.6 pct)
Operating 28.12 28.56 33.00
(-1.5 pct) (+7.5 pct) (-10.8 pct)
Recurring 36.16 33.38 42.50
(+8.3 pct) (+6.4 pct) (+0.9 pct)
Net 51.40 26.46 52.50
(+94.2 pct) (+11.8 pct) (+65.7 pct)
EPS 643.93 yen 331.19 yen 657.75 yen
EPS Diluted 643.33 yen 330.92 yen
Ann Div 110.00 yen 110.00 yen
-Q2 div 50.00 yen 50.00 yen
-Q4 div 60.00 yen 60.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10